Bristol-Myers Squibb Company BMY

Bristol-Myers Squibb's revenue is significantly driven by its investments in research and development (R&D) and selling, general, and administrative (SG&A) expenses, with elasticity estimates indicating that a 1% increase in R&D leads to a 1.16% revenue boost and a 1% increase in SG&A results in a 1.38% increase. The company's recent quarterly revenue of $12.5 billion demonstrates the effectiveness of its spending strategies, supported by a low 4.3% MAPE in model accuracy and a close holdout test prediction. Looking ahead, the forecasted FY revenue of $49 billion reflects a solid 1.4% year-over-year growth, suggesting a positive outlook for investors as the company continues to leverage its investments for sustainable growth.